Geron Corporation (GERN)
After hours:
- Business Wire
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
FOSTER CITY, Calif., September 09, 2024--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appointment of Jim Ziegler as Executive Vice President, Chief Commercial Officer, effective today, September 9, 2024. In this role, Mr. Ziegler will spearhead Geron’s global commercial strategy and operations, lead the commercial organization and be responsible for driving growth of RYTELO™. Mr. Ziegle
- Simply Wall St.
High Growth Tech Stocks To Watch In September 2024
In the last week, the market has been flat, yet it is up 23% over the past year with earnings expected to grow by 15% per annum over the next few years. In this environment, identifying high-growth tech stocks that can capitalize on these favorable conditions becomes crucial for investors looking to maximize their returns.
- Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., August 22, 2024--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 261,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
